SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (715)4/22/1999 11:44:00 PM
From: yosi s  Respond to of 1386
 
The only thing that PARS tamoxiphen analog act as antiangiogenesis.
And in animal model showed to decrease tumor size.
This is much more than tamoxiphen .
That is why the product is very interesting.
Also the potential market is big.
Thre are many Beta blockers, many h2 blockers and many calcium channel blockers etc etc .

So each has its own indication and finds its niche.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News